31 July 2019
Visiongain has launched a new pharma report Global Stem Cell Technologies and Applications Market 2019-2029: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications.
Visiongain believes that the next ten years in the stem cell market will see many crucial breakthroughs, including: multiple approvals, particularly in the cardiovascular segment but increasingly also in the CNS segment; increased use and clinical validation of hESCs and iPSCs; and major changes in the drug development process, enabled by new stem cell-based assays. Visiongain anticipates this change will be evolutionary, rather than revolutionary. Once the current wave of pipeline products has begun to validate itself in the clinic and the marketplace, the groundwork will be laid for the real healthcare paradigm shift that stem cells may finally make possible.
The lead analyst of the report commented "New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market. Scalability is often cited as one of the major barriers in translating promising pre-clinical and clinical-stage results into a valid and commercially viable therapy.
Manufacturing requirements mean that stem cell companies are less able to take advantage of economies of scale and face greater problems with storing and transporting cell products that require sterile conditions and a narrow temperature range. Reimbursement is another difficult area for stem cell products."
Leading companies featured in the report include Mesoblast, Pharmicell, NuVasive, Orthofix, MEDIPOST, Reliance Life Sciences, Gamida Cell, Neuralstrem, ReNeuron, Apceth, Novartis, TiGenix, Ocata Therapeutics, Athersys.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.
20 September 2019
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.